- Instructions for medications
- Dialek
Scientific and Production Unitary Enterprise Dialek, Republic of Belarus INSTRUCTIONS (information for specialists) on the medical use of the drug
- Compound
- Pharmacotherapeutic group
- Pharmacological properties
- Indications for use
- Directions for use and dosage regimen
- Side effect
- Contraindications
- Overdose
- Precautionary measures
- Interaction with other drugs
A16.
OTHER REMEDIES FOR THE TREATMENT OF DISEASES OF THE DIGESTIVE TRACT AND METABOLIC DISORDERSHerbal remedies (a16ax) General characteristics : Transparent solution of reddish-brown color. During storage, sediment may form.
Compound
for 50 ml per 100 ml Diarotocan (alcoholic extract from a mixture of chamomile flowers, marigold flowers, yarrow herb) - 30 ml - 60 ml Diagiperone (tincture of St. John's wort herb) - 10 ml - 20 ml Salvia officinalis leaves tincture - 10 ml - 20 ml Contains at least 64% ethanol.Cordiamin dosage
The drug is administered intravenously, intramuscularly and subcutaneously.
Adults and children over 14 years of age are administered subcutaneously, intramuscularly and intravenously in a dose of 1-2 ml 1-3 times a day.
Intravenous administration is carried out slowly.
For children - subcutaneously, depending on age, in a dose of 0.1-0.75 ml.
Since subcutaneous and intramuscular injections of the drug Cordiamin are painful, to reduce pain, depending on the situation, procaine (Novocaine) 1 ml of 0.5% solution is first injected into the site of the intended injection.
Higher doses for adults subcutaneously: single - 2 ml, daily - 6 ml.
Directions for use and dosage regimen
For topical use.
Before use, 1 teaspoon of the drug is diluted in a glass of water.
For inflammatory diseases of the pharynx, use a solution of the drug 3-4 times a day for 5-7 days.
For stomatitis and other diseases of the oral mucosa, rinses (1-2 minutes) or applications (15-20 minutes) are prescribed 2-3 times a day for 2-5 days. For periodontal disease, after curettage of the necrotic tissue contents of the gingival pockets and removal of dental plaque, thin turundas, generously moistened with a solution of the drug, are inserted into the pockets. Application time – 20 minutes. The course of treatment is 4-6 days.
In the form of microenemas and external irrigations.
For microenemas - 1 teaspoon of the drug is diluted in 50-100 ml of warm boiled water. Apply 1-2 times a day after a cleansing enema. The course of treatment is 14 days. Apply napkins moistened with a solution of the drug (lotions) to the area of the anal fissure 1-2 times a day.
Composition and release form Vazotop R (28 tablets)
Vazotop R contains ramipril as an active ingredient and auxiliary components: hypromellose, pregelatinized starch, microcrystalline cellulose, powdered beef flavor, sodium stearyl fumarate, colloidal silicon anhydride and iron oxide. They are tablets for oral administration, oblong in shape with a groove in the middle. Tablets, depending on the amount of ramipril, have different colors: beige - 1.25 mg, yellow - 2.5 mg and pink - 5.0 mg, respectively. Each half of the tablet is marked with the amount of active substance on one side and the Latin letter “V” on the other. 28 tablets are packaged in plastic jars with a moisture-absorbing membrane and a rotating lid. Pack 3 cans in cardboard boxes.
Side effect
If side effects occur, tell your doctor. This applies to all possible side effects, including those not described in this leaflet.
Allergic reactions are possible (skin itching, skin rash, eczema, contact dermatitis), anaphylactic reactions, skin pigmentation.
With prolonged use, it can cause a feeling of bitterness in the mouth, in some cases - a photosensitizing effect (increased sensitivity of the skin to sunlight).
Drug interactions
Enhances the effects of psychostimulants and antidepressants.
Reduces the effect of narcotic analgesics, hypnotics, antipsychotic and antiepileptic drugs, anxiolytics.
Reduces the effectiveness of niketamide: aminosalicylic acid, opiniazid, phenothiazine derivatives and drugs for general anesthesia.
The convulsive effect of the drug is enhanced by reserpine and aminazine.
The pressor effect of niketamide is enhanced by monoamine oxidase inhibitors.
Contraindications
- hypersensitivity to the components of the drug, as well as to plants of the aster family (Asteraceae), such as arnica, ragweed, tansy, wormwood, aster, chrysanthemum.
- period of pregnancy and lactation.
- children under 18 years of age.
- photodermatitis (including history).
- simultaneous use with MAO inhibitors.
- liver diseases, alcoholism, epilepsy, traumatic brain injury and other brain diseases with a decrease in the seizure threshold (when used in the form of microenemas).
pharmachologic effect
Analeptic.
Pharmacokinetics
Absorption is high and does not depend on the route of administration. Subject to rapid metabolism in the liver with the formation of inactive metabolites, excreted mainly by the kidneys.
Pharmacodynamics
Mixed action analeptic. The mechanism of action consists of central and peripheral effects on the nervous system. The central mechanism is associated with a direct effect on the vasomotor center of the medulla oblongata, leading to its excitation and an indirect increase in blood pressure (especially when this center is initially depressed).
The peripheral effect is due to the stimulation of the chemoreceptors of the carotid sinus, which leads to an increase in the frequency and depth of respiratory movements. Does not have a direct effect on the cardiovascular system.
Precautionary measures
During storage, a slight sediment may appear, which does not affect the effectiveness of the drug.
Contains at least 64% ethanol. Due to the ethyl alcohol content, it is not recommended to take the medicine for a long time.
During treatment, direct sunlight should be avoided due to the possible development of photosensitivity, especially in people with fair skin.
If symptoms persist or worsen while using the drug, you should consult a doctor.
Use during pregnancy and lactation
If you are pregnant or breastfeeding, think you may be pregnant, or think you might be pregnant, tell your doctor.
The drug is not recommended for use during pregnancy and lactation due to the lack of adequate data on the safety of the use of these herbal remedies and alcohol content.
Effect on the ability to drive a car or use other machinery
The medicine contains ethyl alcohol! During the treatment period, it is necessary to refrain from driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Children
The drug is not intended for children under 18 years of age due to the lack of adequate data on the safety of use and ethanol content.
Pharmacological properties
Vasotope R is an antihypertensive drug. Ramipril, which is part of the drug, is an angiotensin-converting enzyme (ACE) inhibitor, which, by suppressing the synthesis of angiotensin II, reduces its vasoconstrictor effect and stimulating effect on aldosterone secretion, and also inhibits the breakdown of bradykinin. Ramipril does not have a significant effect on renal blood flow (in some cases it increases it) and on the glomerular filtration rate. The drug does not cause the development of compensatory tachycardia. The maximum hypotensive effect develops 1 to 3 hours after taking the drug and continues throughout the day. With daily intake of Vasotope R, the decrease in blood pressure occurs gradually over 3 to 4 weeks and remains within the physiological norm throughout the entire treatment period. Abrupt withdrawal of the drug does not lead to a rapid increase in blood pressure. Vasotope P has a cardioprotective effect due to the inhibition of ACE in the myocardium and the accumulation of bradykinin, and also promotes the reverse development of myocardial hypertrophy in animals with arterial hypertension. After oral administration, ramipril is rapidly absorbed in an amount of at least 50–60% of the dose taken. The primary metabolism of ramipril occurs in the liver. In this case, a derivative of ramipril is formed - ramiprilat. Ramiprilat is approximately 6 times more potent in inhibiting ACE than ramipril. Plasma protein binding is 73% for ramipril, and 56% for ramiprilat. After a daily single dose of Vasotope R, a steady-state plasma concentration of ramiprilat is achieved by day 4. About 60% of the drug is excreted in the urine and about 40% in the feces (mainly in the form of metabolites). In case of impaired renal function, the excretion of ramipril and its metabolites slows down in proportion to the decrease in creatinine clearance. According to the degree of impact on the body of warm-blooded animals, Vasotope Rot is classified as a low-hazard substance.
Interaction with other drugs
If you are currently or have recently taken other medications, tell your doctor.
Clinically significant drug interactions with other drugs have not been established.
The simultaneous use of other medications containing ethyl alcohol should be avoided.
Interactions associated with the presence of ethyl alcohol in the composition:
- drugs that cause a disulfiram-like reaction (feeling of heat, redness of the skin, vomiting, tachycardia) when taken together with alcohol: disulfiram, cefamandole, cefoperazone, latamoxef, chloramphenicol, chlorpropamide, glibenclamide, glipizide, tolbutamide and other hypoglycemic drugs, griseofulvin, metronidazole, ornidazole, tinidazole, ketoconazole, procarbazine.
- drugs that inhibit the functions of the central nervous system.
Due to the content of St. John's wort, simultaneous use with antidepressants, beta-sympathomimetics, and other photosensitizers (for example, tetracycline, sulfonamides, thiazides, quinolones, piroxicam) is not recommended.
The tannic acids present in St. John's wort may interfere with the absorption of iron.
St. John's wort increases the activity of cytochrome CYP3A4 of the P450 system.
St. John's wort can significantly affect plasma concentrations of any drug that is metabolized by the cytochrome P450 system, such as:
- digoxin (the effectiveness of digoxin may decrease, and after stopping taking St. John's wort preparations, the toxicity of digoxin may increase);
- theophylline (St. John's wort reduces plasma theophylline concentrations in patients regularly receiving theophylline);
- oral contraceptives containing ethinyl estradiol and levonorgestrel (there has been a report of the development of acyclic bleeding with simultaneous use of St. John's wort with oral contraceptives containing a combination of ethinyl estradiol and levonorgestrel);
- selective serotonin reuptake inhibitors (possible increased effects and development of serotonin syndrome (increased sweating, tremor, redness, confusion, agitation);
- MAO inhibitors (possible increased effects and development of hypertensive crisis);
- cyclosporine (a decrease in the concentration of cyclosporine in the blood plasma is possible).
Conditions and shelf life
In a place protected from light at a temperature of 15 ° C to 25 ° C.
Keep out of the reach of children.
Shelf life: 2 years. Do not use after the expiration date stated on the package.
in bottles of 100 ml in package No. 1; in bottles of 50 ml in package No. 1
Guest, you can leave your comment:
Doses and method of administration
Vazotop R is administered orally once a day, on an empty stomach. The initial therapeutic dose for dogs per day is 0.125 mg of the active ingredient ramipril per 1 kg of animal weight. Animals weighing over 50 kg can be given a daily dose of the drug in two doses. After normalization of blood pressure, treatment with the drug should be continued at half the original dose. For animals at risk of developing hypovolemia, treatment with Vasotope R begins with half the dose, which is given over the course of a week. In the absence of a decrease in blood pressure while taking Vasotope R, to enhance the therapeutic effect, the simultaneous use of diuretics (except for potassium-sparing ones) is allowed in doses according to the instructions for use. In case of congestion in the lungs, two weeks after starting to use the drug, the daily dose can be increased to 0.25 mg of ramipril per 1 kg of animal weight. The duration of the course of therapy is determined by the veterinarian.
